JW Life Science Launches Korea's First Fully Automated Total Parenteral Nutrition Solution Production Line

[Asia Economy Reporter Lee Chun-hee] JW Life Science announced on the 11th that it has completed the expansion of the new production facility 'TPN Line 3' for total parenteral nutrition (TPN) at its intravenous solution factory in the Dangjin Production Complex, Chungnam, and has begun full-scale production.

TPN Line 3 is a total parenteral nutrition production facility capable of producing all volumes, from medium and large volumes of 1000 ml or more to small volumes around 200 ml. The process, including drug filling, sterilization, and packaging, is automated, enabling production of 1,000 units per hour (33 million units annually). This is the first time in Korea that an automated production line capable of producing total parenteral nutrition solutions of all volumes has been established. JW Life Science plans to utilize TPN Line 3 for the country's first small-volume total parenteral nutrition solution to be launched this month and for a new concept intravenous solution production line being developed with Baxter in the United States.

Total parenteral nutrition solutions are products divided into 2 to 3 chambers in one container, each containing essential nutrients such as glucose, amino acids, and lipids. During storage and transport, the separated chambers are maintained, and at the time of use, the chambers are broken to mix the components for administration.

With the full operation of TPN Line 3, JW Life Science's maximum annual production of total parenteral nutrition solutions increased by 37%, from the previous 10.2 million units to 14 million units. This production increase is the result of JW Life Science's continuous expansion of intravenous solution production facilities. In 2017, it established TPN Line 2, the world's largest fully automated production facility dedicated to medium and large volume total parenteral nutrition solutions, capable of producing 2,000 units per hour and 8 million units annually. Currently, it produces Winnerf Injection (domestically sold by JW Pharmaceutical) and Pinomel Injection (globally sold by Baxter). In July, an additional line for the basic intravenous solution production line, TF Line 2, was also expanded.

JW Life Science currently operates a total of six production lines for single-bag basic, nutritional, and lipid intravenous solutions, securing an annual production capacity of 108.34 million single-bag intravenous solutions. Including multi-chamber bag total parenteral nutrition solutions, the maximum annual production volume of bagged intravenous solutions reaches 122.2 million units, the largest in Korea. Including plastic container intravenous solutions, the annual production volume increases to 180 million units.

A JW Life Science official said, "The expansion of TPN Line 3 is an achievement that consolidates JW Life Science's own facility technology capabilities, establishing a stable domestic and international supply base for high value-added total parenteral nutrition solutions. We will further accelerate the development of next-generation intravenous solutions to achieve results in the global market."

This content was produced with the assistance of AI translation services.